151 results about "Male erectile dysfunction" patented technology

Therapeutic devices and methods according to embodiments of the invention alleviate e.g. urinary incontinence in female and male patients. Suction or vacuum, for example, is applied to the genital region, clitoris or clitoral region, the external urethral orifice, and/or other designated areas, e.g. physically stimulating the sacral/pudendal nerves and/or nerve roots and alleviating incontinence. Such embodiments also can encourage or cause clitoral engorgement, or otherwise promote blood flow in the genital region. Vacuum or suction applied to e.g. the clitoris creates a negative pressure in the clitoris that is lower than the systolic blood pressure, tending to promote engorgement of the clitoris with blood. Aspects of the invention are applicable not only to treatment of urinary and fecal incontinence, but also to the treatment of female sexual dysfunction. Aspects of the invention are also applicable to treatment of male incontinence and male erectile dysfunction.

The present invention relates to a transdermal hydroalcoholic testosterone gel formulation that overcomes the problems associated with other testosterone delivery mechanisms by providing, among other things, a desirable pharmacokinetic hormone profile with little or no skin irritation. The gel may be used as a method of improving sexual performance, including treating erectile dysfunction, and increasing libido by increasing testosterone levels in men. In addition, the gel may be used in conjunction with pharmaceuticals aimed at treating erectile dysfunction, such as VIAGRA®, to enhance their effectiveness.

Multiple agent therapy for treatment of sexual dysfunction, including male erectile dysfunction, with sequential administration a type V phosphodiesterase inhibitor (PDE-5), such as sildenafil, preferably wherein the PDE-5 inhibitor is administered by oral dose means, and a melanocortin 3 and/or 4 receptor agonist, such as Ac-Nle-cyclo(-Asp-His-D-Phe-Arg-Trp-Lys)-OH (PT-141) preferably wherein the PT-141 is formulated for and administered by intranasal means, and further preferably wherein the PDE-5 inhibitor is administered prior to PT-141.

A melanocortin receptor agonist cyclic peptide of the formula

where R, x and y are as defined in the specification, compositions and formulations including the peptide of the foregoing formula, and methods of preventing, ameliorating or treating melanocortin receptor-mediated diseases, indications, conditions and syndromes, including sexual dysfunction such as male erectile dysfunction and female sexual dysfunction.

A treatment for male erectile dysfunction comprising separately storing a lyophilized composition of vasoactive agents and a carrier gel, mixing said lyophilized composition of vasoactive agents and said carrier gel creating a homogeneous mixture and applying said homogeneous mixture to the meatus of the glans penis. A system for the treatment of male erectile dysfunction comprising a syringe coupling system for the storage, mixing and application of therapeutic compounds for the treatment of erectile dysfunction, said system further comprising a first syringe and a second syringe. The first and second syringes are filled with a lyophilized composition of vasoactive agents or a carrier gel. The system includes a locking device coupling said syringes to facilitate the transfer of said lyophilized composition of vasoactive agents and carrier gel between the syringes and a penile adapter for applying the therapeutic compounds for the treatment of erectile dysfunction to the meatus of the glans penis.

Polynucleotide and polypeptide sequences are described. The polypeptide sequences comprise one or more of: (a) a polypeptide having the deduced amino acid sequence translated from the polynucleotide sequence in SEQ ID NO: 1 or SEQ ID NO: 5 and variants, fragments, homologues, analogues and derivatives thereof; (b) a polypeptide of SEQ ID NO: 2 and variants, fragments, homologues, analogues and derivatives thereof; (c) a polypeptide encoded by the cDNA of NCIMB 41110 and variants, fragments, homologues, analogues and derivatives thereof; or (d) a polypeptide which has at least 78% identity to (i) the polypeptide encoded by the polynucleotide of SEQ ID NO: 1 or SEQ ID NO: 5, (ii) the polypeptide of SEQ ID NO: 2, or (iii) the polypeptide encoded by the cDNA of NCIMB 41110. Such polypeptide sequences are, inter alia, useful in the prophylaxis and/or treatment of sexual dysfunction, in particular male erectile dysfunction (MED) or female sexual dysfunction (FSD), preferably female sexual arousal disorder (FSAD).

The present disclosure is directed to chemically-stable and pharmaceutically-acceptable sildenafil oral spray formulations for the treatment of male erectile dysfunction, wherein the oral spray formulation has a pH of about 1.5 to less than 3.0. The present disclosure is also directed to methods for treating male erectile dysfunction.

The invention relates to an oral medicinal preparation of tadalafil and application of the preparation in treatment of male erectile dysfunction. The preparation is characterized in that the main medicne is tadalafil or salt thereof, and the particular formulation can be orally disintegrating tablets, chewable tablets, oral membranes and other preparations capable of being quickly released in the oral cavity; tadalafil is an insoluble medicament, and is low in bioavailability, so that the administrated infective dose is large, multiple adverse responses can be generated, and visual impairment or loss can be caused due to unreasonable administration. Regarding the researches of tadalafil medicinal preparation for improving medicament bioavailability and reducing occurrence of adverse responses, the wide clinical application of tadalafil in treatment of male erectile dysfunction is particularly important. Aiming at the fact that the tadalafil medicinal preparation brings great favor to broad ED patients in improvement of the compliance when the tadalafil medicinal preparation is taken by a patient, particularly in administration in an environment without water and in a non-swallow mode. The oral medicinal preparation is prepared through massive studies based on patients.

The present invention relates to methods of treating and preventing obesity and obesity-related disorders in a subject comprising administering a neurokinin-1 antagonist and an anti-obesity agent, such as a melanocortin 4 receptor agonist, to said subject. The present invention further related to methods of treating or preventing sexual dysfunction, including male erectile dysfunction, in a subject comprising administering a neurokinin-1 antagonist and a sexual dysfunction therapeutic agent, such as a melanocortin 4 receptor agonist, to said subject. The present invention further provides for pharmaceutical compositions and medicaments useful in carrying out these methods.

This invention is directed toward herbal compositions and methods of treatment for prevention or treatment of erectile dysfunction disorders and ameliorating symptoms thereof and as a preventative measure against erectile dysfunction. The methods comprise administering a therapeutically effective composition of matter comprising the following herbal and other components: Herba cynomorii, Rhizhomnas atractylodis macrocephalae, Radix rehmannia glutinosea longui, Herba epimedii, Fructus lycii, Fructus schisandrae chinensis, Radix poloygoni multiflor, Cortex cinnamonia cassiae, Fructus amoni, and Radix ginseng. The components of the invention interact synergistically once consumed to remedy or prevent erectile dysfunction when taken as prescribed. The invention is completely herbal in composition and does not contain any hormones, morphine, or any of the compositions of matter know by trade names Viagra, Cialis, Sildenafil or Vardenafil. Side benefits of taking this dietary supplement include increased energy, improved immune system strength, and improved erectile activity in men without erectile dysfunction.

Disclosed are methods and compositions for treatment of male sexual dysfunction. A method of treating male sexual dysfunction includes administering a pharmaceutical composition effective to cause said male to sustain an erection. The composition is formulated based on diagnostic assessment and an individualized formulation test step. Also within the invention is a method of treating male sexual dysfunction in a population of subjects. The invention further provides kits for treatment of male erectile dysfunction.

The invention discloses pulse ultrasound treatment equipment for male erectile dysfunction.The pulse ultrasound treatment equipment comprises a master control device, a micro-control system and a treatment probe.The treatment probe comprises an ultrasound generator.The master control device sends control signals to the micro-control system, the micro-control system converts the control signals into control instructions and sends the control instructions to the ultrasound generator, and the ultrasound generator generates corresponding ultrasound according to the control instructions.The pulse ultrasound treatment equipment can generate the ultrasound for therapeutic use, treatment is conducted in vitro in a non-intrusive mode, pain brought to a patient by an operation is avoided, and harm of medicine to the human body of dependence of the human body on the medicine are avoided.The low-intensity pulse ultrasound can promote neovascularization, proliferation of cavernous body smooth muscle cells and eNOS and nNOS expression, improve blood flow of the penis, lower a TGF-beta1/Smad/CTGF signal channel and relieve fibrosis of the penis, the pathological change of the erection organ is improved accordingly, and finally the erection function of the penis is improved.

The present invention belongs to the field of research and development of medicines and health-care products, and provides new applications of NADH and/or NMN in preparing medicines and/or health-care products for prevention and treatment of male erectile dysfunctions. Administration of the NADH/NMN can activate nitric oxide synthase, thus stimulates a synthesis amount of nitric oxide, and has significant prevention and treatment effects on the male erectile dysfunctions caused by NO synthesis disorder.

The invention discloses a medicament for the treatment of functional disturbance of men's erection, which is made up of L-arginine with the mass ratio of 30-95% and a solid agent or a liquid agent with the mass ratio of 5-70%. The medicament can be made into capsules, drinkable solution, pills, and tablets, dripping or spraying agent, suppository or patches. The medicament can be take by oral administration, or administered through tongue, nasal cavity, rectal intestine, or skin, and the medicament which contains L-arginine of 1-2.7 g, 2.9-4.9 g, or 5.1-10.0 g is taken everyday for 2- 8 weeks or more constantly or discontinuously. The medicament has the advantages of low price, good erecting effect, high safety, few side effects, and many aggregate effects, and the medicament also can improve the heart functions of patients who suffer form congestive heart failures, enhance immunologic function, and prevent oxidation, age and arteriosclerosis. The invention is safer than Viagra for patients who suffer ED and especially the patients who have had heart disease.

The invention relates to a method for extracting a burdock root aqueous extract and application thereof. The extraction method comprises the following steps: burdock root is removed with impurities, is cleaned, is sliced, is added with water of 6 to 8 times of the weight of the burdock root, is decocted and is filtered to obtain a primary liquid medicine; medicine residue is added with water of three times of the weight of the medicine residue, is decocted and is filtered to obtain a secondary liquid medicine; two filtrates are mixed and condensed to form a water decocted liquid medicine with concentration of 2 g/ml; the water decocted liquid medicine is filtered with a solid content and is condensed, frozen and dried to obtain the dry powder of the burdock root extract; and the obtained dry powder of the burdock root extract contains 95 to 98 percent of amylose. The burdock root aqueous extract as a medicine raw material and a functional food raw material is respectively prepared into a capsule preparation, a troche, a powder preparation, a granule preparation, an oral liquid preparation or a compound preparation according to the prior preparation method. The burdock root aqueous extract can be used for preventing and treating male erectile dysfunction.

A melanocortin-4 receptor agonist cyclic peptide of the formula

where R₁, R₂, R₃, R_4a, R_4b, R₅, R₆, R_7a, R_7b, x, y and z are as defined in the specification, and a method of treating sexual dysfunction, including male erectile dysfunction and female sexual dysfunction, and other melanocortin 4 receptor responsive conditions and disorders.

Agents of formula: where R1 and R2 vary independently and are acyl, sulfonyl, phosphoryl, alkyl, substituted alkyl, halogen, aryl, arylalkyl, substituted aryl, heteroaryl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, heterocycle, or heteroatoms; and R3 is H or a member of a ring structure which includes R2, are provided; as are agents of formula: where R1, R2 and R3 vary independently and: R1=OH, OR′, NHR′, NR′R″ (with R′ R″=alkyl, aryl, heteroaryl, etc); R²=acyl, alkyl, aryl, sulfonyl, etc; R3=alkyl, aryl, substituted aryl, heteroaryl, etc; and R4 and R5 are (independently) H, methyl or alkyl, substituted alkyl, aryl, substituted aryl, etc. Methods of using the agents to treat e.g. cardiovascular disease, stroke, shock, injuries caused by hypoxia, male erectile dysfunction, and Alzheimer's are provided.

L-citrulline for treatment of endothelial dysfunction and in particular of erectile dysfunction and a pharmaceutical composition comprising L-citrulline in combination with one or more substances selected from the group consisting of pycnogenol, aqueous extract of Viscum album, NADPH, tetrahydrobiopterin, folic acid and mixtures thereof.